Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sanofi said it would buy US biotech Vigil Neuroscience in a deal worth up to $600 million, adding an experimental oral treatment for Alzheimer's disease to its…
Sanofi is expanding its neuroscience drug pipeline through the $470 million acquisition of Vigil Neuroscience, a clinical-stage biotech with a drug that could…
Sanofi announced today the successful completion of its acquisition of Vigil Neuroscience, adding VG-3927, an oral small-molecule TREM2 agonist in Phase…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Sanofi agreed to acquire Vigil Neuroscience for $8.00/share cash plus non-tradeable CVR of $2.00/share tied to first commercial sale of VG-3927, for total equity value up to ~$600M. Adds oral TREM2 agonist for Alzheimer's disease to Sanofi's neurology pipeline.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Vigil Neuroscience, Inc. (this deal) | 2025 | $600M | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2025 deals · Sanofi SA deals · Neurology deals